| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
Divisions of Adolescent/Young Adult Medicine (C.M.G., E.G., S.J.E., K.A.B.) and Endocrinology (C.M.G.), Clinical Research Program (H.A.F.), Children’s Hospital, Boston, Massachusetts 02115; Division of Adolescent Medicine, Children’s Hospital of Cincinnati (E.G.), Cincinnati, Ohio 45229-3039; Maine Center for Osteoporosis, St. Joseph Hospital (C.J.R.), Bangor, Maine 04402; Department of Orthopedics, Yale-New Haven Hospital (C.M.G.), New Haven, Connecticut 06510; and Division of Endocrine/Hypertension, Brigham and Women’s Hospital (M.S.L.), Boston, Massachusetts 02115
Address all correspondence and requests for reprints to: Catherine M. Gordon, M.D., M.Sc., Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115. E-mail: catherine.gordon{at}tch.harvard.edu.
Abstract
Young women with anorexia nervosa (AN) have subnormal levels of dehydroepiandrosterone (DHEA) and estrogen that may be mechanistically linked to the bone loss seen in this disease. The purpose of this study was to compare the effects of a 1-yr course of oral DHEA treatment vs. conventional hormonal replacement therapy (HRT) in young women with AN.
Sixty-one young women were randomly assigned to receive oral DHEA (50 mg/d) or HRT (20 µg ethinyl estradiol/0.1 mg levonorgestrel). Anthropometric, nutrition, and exercise data were acquired every 3 months, and bone mineral density (BMD) and body composition were measured by dual energy x-ray absorptiometry (DXA) every 6 months over 1 yr. Serum samples were obtained for measurements of hormones, proresorptive cytokines, and bone formation markers, and urine was collected for determinations of bone resorption markers at each visit.
In initial analyses, total hip BMD increased significantly and similarly (+1.7%) in both groups. Hip BMD increases were positively correlated with increases in IGF-I (r = 0.44; P = 0.030) and the bone formation marker, bone-specific alkaline phosphatase increased significantly only in the DHEA treatment group (P = 0.003). However, both groups gained significant amounts of weight over the year of therapy, and after controlling for weight gain, no treatment effect was detectable. There was no significant change in lumbar BMD in either group. Both bone formation markers, bone-specific alkaline phosphatase and osteocalcin, increased transiently at 6–9 months in those subjects receiving DHEA compared with the estrogen-treated group (P < 0.05). Both DHEA and HRT significantly reduced levels of the bone resorption markers, urinary N-telopeptides (P < 0.05). There was a positive correlation between changes in IGF-I and changes in weight, body fat determined by DXA, and estradiol for both groups. In addition, patients receiving DHEA exhibited improvement on three validated psychological instruments (Eating Attitudes Test, Anorexia Nervosa Subtest, and Spielberger Anxiety Inventory).
Both DHEA and HRT had similar effects on hip and spinal BMD. Over the year of treatment, maintenance of both hip and spinal BMD was seen, but there was no significant increase after accounting for weight gain. Compared with HRT, DHEA appeared to have anabolic effects, evidenced by the positive correlation between increases in hip DXA measurements and IGF-I and significant increases in bone formation markers. Both therapies significantly decreased bone resorption. Replicating results from studies of the elderly, DHEA resulted in improvements in specific psychological parameters in these young women.
This article has been cited by other articles:
 |
|
 |
|
  A Hartkamp, R Geenen, G L R Godaert, H Bootsma, A A Kruize, J W J Bijlsma, and R H W M Derksen Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial Ann Rheum Dis, January 1, 2008; 67(1): 91 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Miller, E. A. Lawson, V. Mathur, T. L. Wexler, E. Meenaghan, M. Misra, D. B. Herzog, and A. Klibanski Androgens in Women with Anorexia Nervosa and Normal-Weight Women with Hypothalamic Amenorrhea J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1334 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wierman, R. Basson, S. R. Davis, S. Khosla, K. K. Miller, W. Rosner, and N. Santoro Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3697 - 3710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Loud and C. M. Gordon Adolescent bone health. Arch Pediatr Adolesc Med, October 1, 2006; 160(10): 1026 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S L Liu and C M Lebrun Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review Br. J. Sports Med., January 1, 2006; 40(1): 11 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The ESHRE Capri Workshop Group Noncontraceptive health benefits of combined oral contraception Hum. Reprod. Update, September 1, 2005; 11(5): 513 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. H. Golden, E. A. Iglesias, M. S. Jacobson, D. Carey, W. Meyer, J. Schebendach, S. Hertz, and I. R. Shenker Alendronate for the Treatment of Osteopenia in Anorexia Nervosa: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3179 - 3185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dolan, S. Wilkie, N. Aliabadi, M. P. Sullivan, N. Basgoz, B. Davis, and S. Grinspoon Effects of Testosterone Administration in Human Immunodeficiency Virus-Infected Women With Low Weight: A Randomized Placebo-Controlled Study Arch Intern Med, April 26, 2004; 164(8): 897 - 904. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
